Angiopoietin 2, VEGF dual antagonists
US11746147B2 · kind B2 · utility
1Cited by
4References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 13, 2020 |
| Grant date | Sep 5, 2023 |
| Priority date | — |
| Expiry date | May 16, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.